Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Massive european study to monitor common colds and flu in real time

NCT ID NCT06282718

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study will follow 2,000 people of all ages who visit their doctor with symptoms of an acute respiratory infection, like cough, sore throat, or runny nose. Researchers will collect information on symptoms, treatments, and lab results to better understand how these infections spread and are managed across Europe. The goal is to build a research network that can quickly launch future studies on new treatments, tests, and vaccines.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study will provide crucial data on how respiratory infections present and are managed in community care, and create a ready-to-use network for future research on treatments, diagnostics, and prevention.
What could go wrong
This is an observational study, not testing any new treatment. It may face challenges in recruitment or data completeness, and results may not apply to all regions or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients of any age group presenting to primary care settings with an ARI.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

POS-ARI-PC AUDIT: Inclusion Criteria: Eligible patients will be of any age consulting (telephone, video, face-to-face) with a participating health care facility with: * Symptoms suggestive of an acute lower RTI with cough as predominant symptom and with illness duration less than 28 days, AND/OR * Symptoms suggestive of an acute upper RTI with sore throat and/or coryza as predominant symptom and with illness duration of less than 14 days AND/OR * Patients otherwise suspected of COVID-19, influenza or RSV. Exclusion Criteria: Patients will not be eligible for if they have withdrawn their consent for anonymous data collection for research by their health care facility. POS-ARI-PC CORE: Inclusion criteria: Eligible patients will be of any age consulting (telephone, video, face to face) with a participating primary health care facility with: * Symptoms suggestive of an acute lower respiratory infection with cough as the predominant symptom, with illness duration less than 28 days, AND/OR * Symptoms suggestive of an acute upper respiratory infection with sore throat and/or coryza as the predominant symptom, with illness duration of less than 14 days AND/OR * Other symptoms suggestive of COVID-19, Influenza, RSV AND * Participant or legal guardian(s) willing and able to provide informed consent and comply with study procedures Exclusion criteria: Patients will not be eligible if: * According to the judgement of the recruiting clinician, they will not be able comply with study procedures, for example because they do not understand the language in which the study is being conducted locally (and have no one to help and translate for them); have a serious psychiatric disorder; or are terminally ill * Symptoms of presumed non-infective origin * Participant requires admission to hospital on the day of inclusion Additional in/exclusion criteria might apply to embedded studies and will be described in the SSA or ISA. POS-ARI-PC-001: Symptoms and Duration Symptoms suggestive of an acute lower RTI with new or increased cough as the predominant symptom, with illness duration ≤10 days; AND/OR Symptoms suggestive of an acute upper RTI with sore throat and/or coryza as the predominant symptom, with illness duration ≤10 days; Age Aged 60 years and over OR Aged 50 to 59 years and have a long-term health condition which makes them eligible for the yearly influenza vaccination under the national influenza vaccination programme; Consent Willing and able to provide informed consent and have a swab taken. Exclusion Criteria: As per the POS-ARI-PC CORE Protocol, with one exception: patients needing hospitalisation can be recruited into the study if timing allows. Patients can provide a swab and decide not to participate in the follow-up procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Limoges

    RECRUITING

    Limoges, France

  • Universiteit Antwerpen

    RECRUITING

    Antwerp, Belgium

  • University of Oxford

    RECRUITING

    Oxford, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.